April 16, 2003

Skinvisible's Antimicrobial Hand Sanitizer Formulation May Offer Potential Advantage Against Transmission of SARS Virus for South Korean Distributor

Skinvisible, Inc. (OTC Bulletin Board: SKVI) (Website: www.skinvisible.com ) announced that it has signed a Distribution Agreement with Canadian-based Clara Laboratories Ltd. granting them the right to distribute Skinvisible's full line of proprietary Invisicare(R) polymer-based delivery systems throughout the South Korean marketplace.

The Agreement also gives Clara Laboratories access to Skinvisible's product formulations which incorporate the Invisicare(R) delivery systems, including an antimicrobial hand sanitizer lotion and a range of skincare moisturizers and sunscreens. Proven advantages of the Skinvisible formulations include their ability to bond with the skin, holding active ingredients in place for extended periods and offering timed release. The formulations resist both wash-off and perspiration while providing longer persistence for skincare, sunscreen, and hand sanitizer products.

Of particular and immediate interest to Clara Laboratories, due to the imminent threat and spread of the SARS virus, is Skinvisible's patent-pending antimicrobial hand sanitizer formulation. Independent studies indicate that this formulation offers significant advantages over alcohol-based hand sanitizers marketed to kill bacteria and viruses on the hands. The Skinvisible formulation offers continuous, long-term kill of up to 4 hours per application, undiminished by hand washing or perspiration. In comparison, the alcohol gels typically provide instant protection but offer no long-term persistence.

'We see this Agreement as a positive and rewarding new venture for Skinvisible,'says Mr. Terry Howlett, the Company's President. 'It makes the most sense to gain exposure in international markets through established local marketers and distributors,'he continues, 'and we are excited to see Skinvisible's patent-pending formulations introduced into South Korea which has significant market potential.'

The founders and management of Clara Laboratories have extensive knowledge and connections within the South Korean market. Discussions are also presently underway for Clara Laboratories to potentially acquire certain rights to the antimicrobial hand sanitizer for the regions of China and Hong Kong where the SARS virus is most prevalent and threatening.

Headquartered in Las Vegas, Nevada, Skinvisible, Inc. is focused on the development of innovative topical polymer-based delivery systems and related technologies incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymers into stable water emulsions. Skinvisible's primary marketing and sales objectives are to license its technologies and/or sell its delivery systems to provide enhanced product performance for established brand manufacturers and providers of prescription, over-the-counter, cosmetic, and skincare products. In addition Skinvisible formulates and manufactures products for private label customers.

This press release contains 'forward looking'statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934 as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports that will be on file with the US Securities and Exchange Commission (including but not limited to the report on Form 10-KSB for the year ended December 31, 2002).

For Further Information Contact: T. Howlett - Skinvisible, Inc. - Ph. (702) 433-7154 / Fax (702) 433-7192 / Email: terry@skinvisible.com

Press Release Index

New Press Release Alerts:

If you are interested in receiving corporate and new product development news from Skinvisible, simply enter your email address below.